ArticleTranslational vision science & technology2026
Proteomic and Clinical Characterization of Active vs. Quiescent Pterygium With Elevated Thrombospondin-1.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate proteomic and clinical changes in active- and quiescent-stage pterygium and identify biomarkers. Methods: This study included 15 and 14 patients with quiescent- and active-stage pterygium, respectively. Clinical parameters (length, area, thickness, vessel density, and hemodynamics) were assessed using slit-lamp, anterior segment-optical coherence tomography angiography, and functional slit-lamp biomicroscopy. Label-free proteomics was performed on excised tissues. Thrombospondin-1 (THBS1) was validated via enzyme-linked immunosorbent assay, immunohistochemistry, and reverse transcription quantitative polymerase chain reaction. Correlation and receiver operating characteristic analyses were also conducted. Results: Compared with the quiescent stage, active pterygium exhibited significantly greater corneal invasion length, area, thickness, and vessel density, along with reduced vessel length. Proteomic analysis revealed 7 upregulated differentially expressed proteins whose pathways were mainly immune related and 15 downregulated differentially expressed proteins. THBS1 was significantly elevated in active tissue, confirmed by enzyme-linked immunosorbent assay, strong immunohistochemical staining, and higher messenger RNA levels. Receiver operating characteristic analysis supported THBS1 as a potential biomarker, yielding an area under the curve of 0.81 for distinguishing active-stage pterygium. Conclusions: Immune dysregulation and neovascularization may play an important role in pterygium progression. THBS1 may serve as a potential biomarker for predicting pterygium development and monitoring its progression. Translational Relevance: This work translates the discovery of elevated thrombospondin-1 into a potential clinical biomarker, bridging proteomic findings to the assessment of pterygium activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.